Melatonin in the saliva of adolescent girls with polycystic ovary syndrome

Abstract

Background. The formation of polycystic ovary syndrome (PCOS) and the manifestation of its clinical manifestations often begin in adolescence. In recent years, one of the new and modern areas in the study of reproductive dysfunction is the problem of melatonin on the gonadotropic function of the pituitary gland (ovariogenesis). The purpose of the study was to determine the level of melatonin in the saliva of adolescent girls with PCOS. Materials and methods. A single-center prospective simple randomi­zed study was conducted with 23 patients aged 14–18 years (inclusive) with PCOS. The control group consisted of 25 girls of the same age without gynecological status violations. Determination of melatonin levels in saliva was performed by high performance liquid chromatography with tandem mass spectrometry (HPLC-MS). Before salivation during the day and throughout the saliva collection period, patients excluded caffeine, alcohol, and exercise, did not smoke for one hour before collection, did not brush their teeth, did not floss, rinsed their mouths, and did not chew gum. Results. There were no significant differences in the age of the girls in the main group and the comparison group (16.70 ± 0.11 years in the main group and 16.90 ± 0.14 years in the comparison group, p > 0.05). The most common symptoms of PCOS in girls were: hypomenstrual syndrome (86.9 %), dermopathy (82.6 %) and hirsutism (60.8 %). Girls with PCOS had significantly higher melatonin levels in saliva (03:00) (28.89 [18.17; 46.53] pg/ml) compared to girls in the comparison group (12.07 [11.56; 16.27] pg/ml, p < 0.01). A pro­bable difference in melatonin levels in saliva depending on age has not been established. Conclusions. The results of the study indicate a violation of hormonal balance in polycystic ovary syndrome, in particular an increase in melatonin levels, which indicates the need to determine it in the process of diagnosis and treatment.

Features of using prolonged-release melatonin in patients with type 2 diabetes

“…Припускаючи, що концентрації в плазмі крові, які перевищують пік ендогенного мелатоніну, є ефективними щодо викликання та підтримки сну, форми мелатоніну із подовженим часом вивільнення можуть бути ефективними протягом усього циклу сну [29,30]. Попри те, що немає чіткого зв'язку між старінням і засвоєнням мелатоніну (хоча встановлено високий ступінь міжіндивідуальної варіабельності), також становить великий інтерес оцінка біодоступності мелатоніну у вікових групах, схильних до порушень сну [31,32].…”